Bobby McMillin | People | Arnold & Porter

Bobby McMillin brings experience in public policy, legislative process, and oversight as both a former congressional staffer and the first in-house D.C. hire for a global life sciences company. He regularly advises clients on how best to advance their policy priorities – including drug pricing, coverage and reimbursement, FDA regulatory matters, and issues like the BIOSECURE Act at the intersection of national security and life sciences policy – with both Congress and the Trump Administration.

He previously served as General Counsel for the Senate Health, Education, Labor, & Pensions (HELP) Committee, where he provided counsel on the full committee's legislative and regulatory oversight portfolio, which includes FDA, NIH, CDC, Health IT and cybersecurity, the 340B program, pandemic preparedness, commercial insurance, and the Department of Education. Bobby also acted as the principal staffer for committee process, rules, and precedents, and he played a leading role in the HELP Committee's work reporting nominees and bipartisan legislation under both the Obama and first Trump administrations. He negotiated agreements with the House, White House, Congressional leadership, other committees, and member offices to advance bills and nominees before the Senate, including the management of House-Senate Conference Committees on major education and opioids legislation.

Previously, Bobby was Counsel for Sen. Saxby Chambliss (R-GA), where his portfolio included health, education, judiciary, and commerce responsibilities, and he has also worked and volunteered on House, Senate, and Presidential campaigns.

After leaving public service, Bobby was the first D.C. government affairs professional for the world's leading genomics company. During the COVID-19 crisis, he coordinated with other healthcare companies, patient groups, and trade associations to secure billions in funding for diagnostic testing, genomic sequencing, analytics, and disease surveillance. He also executed a legislative advocacy plan with the rare disease community focused on increasing access and funding for diagnostics for children on Medicaid suspected to have a genetic disease.